Lipoxygenase inhibitors as potential cancer chemopreventives.
Mounting evidence suggests that lipoxygenase (LO)-catalyzed products have a profound influence on the development and progression of human cancers. Compared with normal tissues, significantly elevated levels of LO metabolites have been found in lung, prostate, breast, colon, and skin cancer cells, as well as in cells from patients with both acute and chronic leukemias. LO-mediated products elicit diverse biological activities needed for neoplastic cell growth, influencing growth factor and transcription factor activation, oncogene induction, stimulation of tumor cell adhesion, and regulation of apoptotic cell death. Agents that block LO-catalyzed activity may be effective in preventing cancer by interfering with signaling events needed for tumor growth. In fact, in a few studies, LO inhibitors have prevented carcinogen-induced lung adenomas and rat mammary gland cancers. During the past 10 years, pharmacological agents that specifically inhibit the LO-mediated signaling pathways are now commercially available to treat inflammatory diseases such as asthma, arthritis, and psoriasis. These well-characterized agents, representing two general drug effect mechanisms, are considered good candidates for clinical chemoprevention studies. One mechanism is inhibition of LO activity (5-LO and associated enzymes, or 12-LO); the second is leukotriene receptor antagonism. Although the receptor antagonists have high potential in treating asthma and other diseases where drug effects are clearly mediated by the leukotriene receptors, enzyme activity inhibitors may be better candidates for chemopreventive intervention, because inhibition of these enzymes directly reduces fatty acid metabolite production, with concomitant damping of the associated inflammatory, proliferative, and metastatic activities that contribute to carcinogenesis. However, because receptor antagonists have aerosol formulations and possible antiproliferative activity, they may also have potential, particularly in the lung, where topical application of such formulations is feasible.
Steele
V E
VE
Chemoprevention Branch, Division of Cancer prevention, National Cancer Institute, Bethesda, Maryland 20892-7322, USA.
Holmes
C A
CA
Hawk
E T
ET
Kopelovich
L
L
Lubet
R A
RA
Crowell
J A
JA
Sigman
C C
CC
Kelloff
G J
GJ
D000818:Animals; D016588:Anticarcinogenic Agents / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use*; D009369:Neoplasms / Q000517:prevention & control*; D051381:Rats
D016588:Anticarcinogenic Agents; D016859:Lipoxygenase Inhibitors